Valuation : BICO Group AB

Market Cap 1.41B 147M 127M 119M 108M 204M 14.03B 205M 549M 7.08B 551M 539M 23.49B P/E 2026 *
-6.19x
P/E 2027 * -11.1x
Enterprise Value 1.34B 140M 120M 113M 103M 194M 13.34B 195M 522M 6.74B 524M 513M 22.33B EV / Sales 2026 *
0.83x
EV / Sales 2027 * 0.74x
Free-Float
69.88%
Yield 2026 *
-
Yield 2027 * -
1 day-26.24%
3 months-28.23%
6 months-1.65%
Current year-33.61%
Current year 0.35
Extreme 0.35
0.65
1 year 0.35
Extreme 0.35
0.75
3 years 0.35
Extreme 0.35
1.55
5 years 0.35
Extreme 0.35
14.8
10 years 0.35
Extreme 0.35
14.8
Manager TitleAgeSince
Chief Executive Officer 54 27/11/2023
Director of Finance/CFO 56 01/03/2026
Chief Operating Officer - 07/01/2026
Director TitleAgeSince
Director/Board Member 70 18/12/2019
Director/Board Member 37 01/03/2015
Director/Board Member - 07/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-26.24%-.--% - - 148M
-1.40%-1.22%+26.93%+14.02% 233B
+0.37%-1.11%+5.42%-17.24% 152B
+1.53%-1.58%-21.32%+23.67% 130B
+0.03%-7.19%-55.79%-13.09% 67.64B
+0.15%+0.53%+11.12%+18.72% 51.85B
+0.66%-1.69%-16.57%-13.62% 50.91B
-1.91%-2.69%+23.82%+29.03% 44.46B
-1.31%+1.12%+39.52%+47.56% 41.39B
+2.22%+3.65%-12.86%+48.24% 34.01B
Average -2.64%-0.44%+0.03%+15.25% 89.42B
Weighted average by Cap. -0.17%-0.56%+3.17%+9.96%

Financials

2026 *2027 *
Net sales 1.62B 169M 146M 137M 125M 235M 16.17B 236M 633M 8.16B 635M 621M 27.07B 1.69B 176M 152M 142M 130M 244M 16.81B 245M 658M 8.48B 660M 646M 28.13B
Net income -227M -23.68M -20.41M -19.13M -17.47M -32.9M -2.26B -33.01M -88.57M -1.14B -88.91M -86.98M -3.79B -126M -13.14M -11.33M -10.62M -9.69M -18.26M -1.26B -18.32M -49.16M -634M -49.35M -48.28M -2.1B
Net Debt -69M -7.2M -6.2M -5.82M -5.31M -10M -688M -10.03M -26.92M -347M -27.03M -26.44M -1.15B -166M -17.32M -14.92M -13.99M -12.77M -24.06M -1.66B -24.14M -64.77M -836M -65.02M -63.61M -2.77B
Logo BICO Group AB
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Employees
554
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
19.94SEK
Average target price
29.00SEK
Spread / Average Target
+45.44%

Quarterly revenue - Rate of surprise